For the past five decades, there has been little progress in the development of oral
anticoagulants, with the choices being limited to the vitamin K antagonists (VKAs). The …

The activated serine protease factor Xa is a promising target for new anticoagulants. After
studies on naturally occurring factor Xa inhibitors indicated that such agents could be …

Background Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent
ischemic events when added to antiplatelet therapy after an acute coronary syndrome …

Background There are various regimens for thromboprophylaxis after hip replacement. Low-
molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also …

Background Low-molecular-weight heparins such as enoxaparin are preferred for
prevention of venous thromboembolism after major joint replacement. Apixaban, an orally …

Aims To evaluate apixaban single dose safety, tolerability, pharmacokinetics and
pharmacodynamics and assess the effect of food on apixaban pharmacokinetics. Methods A …

The metabolism and disposition of [14C] apixaban, an orally bioavailable, highly selective,
and direct acting/reversible factor Xa inhibitor, was investigated in 10 healthy male subjects …

Background The optimal strategy for thromboprophylaxis after major joint replacement has
not been established. Low-molecular-weight heparins such as enoxaparin predominantly …

Aim Apixaban is an oral factor X a inhibitor approved for stroke prevention in atrial fibrillation
and thromboprophylaxis in patients who have undergone elective hip or knee replacement …

Aim Apixaban is an oral, direct, factor‐X a inhibitor approved for thromboprophylaxis in
patients who have undergone elective hip or knee replacement surgery and for prevention …